This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Former Senator Ben Sasse has become an unlikely public face of a drug that researchers are ...

Revolution Medicines said its pancreatic cancer drug daraxonrasib succeeded in a Phase 3 trial. RevMed said its drug almost doubled the typical length of survival and slashed the risk of death by 60% ...

Former Sen. Ben Sasse (R-Neb.) detailed his battle with cancer and reflected on his life during a wide-ranging interview with The New York Times’s Ross Douthat. The conversation, released Thursday as ...

Raphael was believed to be 17 when he did this chalk sketch, likely a self-portrait. "What is really extraordinary is the perfection of his technique in drawing," said curator Carmen Bambach. You can ...

The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patients, ...

A new blood test could change the outlook for one of the deadliest cancers—pancreatic cancer—by catching it much earlier than ever before. Researchers identified two previously unknown proteins in the ...

Pancreatic cancer continues to be a devastating disease, with an overall 5-year survival rate of around 13%. Accounting for about 3% of all cancers, it is the third leading cause of cancer death in ...

FDA approved Optune Pax with gemcitabine/nab-paclitaxel, applying alternating electric fields to disrupt mitosis via abdominal arrays, expanding noninvasive, home ...

Current drugs for pancreatic cancer lose effectiveness within months because the tumor becomes resistant. Now, a group from Spain's National Cancer Research Centre (CNIO) has been able to avoid the ...

Researchers in Spain have developed a new therapy protocol that could revolutionize the treatment of pancreatic cancer. Notoriously aggressive and difficult to treat, pancreatic cancer is rarely ...

CLEVELAND, Ohio — Pancreatic cancer stands apart from many common cancers for a troubling reason: There is no standard screening test to catch the disease early, when treatment is most effective. That ...